

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Lymphoma Committee

Lymphoma Committee

Leadership

Chair: Sonali M. Smith, MD
 Vice-Chair: Jennifer E. Amengual, MD
 Executive Officer: Alex Herrera, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Thiruvengadam, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Adolescent & Young Adults: Boyu Hu, MD
 Cancer Control: TBD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Dawud Nael Dawud Ellayan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers, MS
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, October 8, 2026 5:00 p.m. - 7:00 p.m.
 Room: Regency C (Ballroom Level)

Agenda

Welcome & Introductions - Sonali Smith, MD & Jennifer Amengual, MD

A Note from Our Patient Advocate - Tricia Hernandez, MS

The Future of DLBCL: Are We There Yet?

1. Evolving strategies in 1L DLBCL: precision vs. targeted treatment - Patrick Reagan, MD
2. SWOG approach to RR DLBCL - Brian Hess, MD & Jennifer Amengual, MD
3. Is ctDNA ready for primetime in DLBCL? - Jeff Cherng, MD

SWOG Trial Updates

- | | | |
|----|-------|-----------------------|
| 1. | S1918 | Elizabeth Brem, MD |
| 2. | S2114 | Brian Hess, MD |
| 3. | S2207 | Jennifer Amengual, MD |
| 4. | S2308 | Nilanjan Ghosh, MD |
| 5. | S2506 | Boyu Hu, MD |
| 6. | S1925 | Debbie Stephens, DO |
| 7. | S2504 | Mazyar Shadman, MD |

Open Studies From Other Groups

- | | | |
|----|---------|-----------------------|
| 1. | A051902 | Jennifer Amengual, MD |
| 2. | A052101 | Tyler Phillips, MD |
| 3. | EA4232 | Marc Hoffmann, MD |

Good Hang with AYA: Ongoing Collaborations Between COG and SWOG

Sharon Castellino, MD & COG Colleagues

Active Studies

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. B. Hess and N. Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/2023.

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. N. Ghosh and J. Friedberg. Activated: 8/1/2024.

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. B. Hu, B. Hu, and S. Smith. Activated: 8/10/2026.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 09/08/2023.

Lymphoma Committee

CTSU/AHOD2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 04/28/2023.

CTSU/EA4232, "A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Response (CR1) Following Induction Therapy (PTCL-STAT)." Dr. Bennani. SWOG Champion: Dr. M. Hoffmann. Activated: 1/30/2025.

Closed Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/2024.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. E. Brem and S. Smith. Activated: 3/19/21. Closed: 4/24/26.

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/2021. Closed: 5/28/25.

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17. Closed 10/3/24.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients $\leq$ 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023.

Active Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. D. Stephens. Activated: 12/14/20.

S2504, "A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants with Previously Untreated Richter Transformation (PIRAMID)." Drs. M. Shadman, D. Stephens, and A. Danilov. Activated: 6/1/2026.

Closed Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. V. Shankaran. Activated 7/26/2021. Closed 12/16/2024.

Lymphoma Committee

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1001/Others Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma. Chen Z, Luan D, Jørgensen RRR, Jakobsen L, Maurer MJ, El-Galaly TC, Nastoupil LJ, Cerhan JR, Flowers CR, Link BK, Lossos IS, Stephens DM, Cohen J, Habermann TM, Nowakowski G, Bartlett N, Friedberg JW, Kahl BS, Leonard JP, Brown P, Smedby KE, Jerkeman M, Martin P. *American Journal of Hematology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42240061/>

S1826 Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Ahmed S, Li H, Herrera AF, Perry AM, Kovach AE, Rutherford SC, Davison K, Castellino SM, Evens AM, Kahl B, Bartlett NL, Leonard JP, Shipp MA, Smith SM, Kelly KM, LeBlanc M, Friedberg JW, Song JY. *Blood Advances*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42526889/>

S1826 Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma. Goyal G, Lurain K, Lopez G, Rutherford SC, Castellino S, Davison K, Evens A, Smith SM, Kelly K, LeBlanc M, Song JY, Odeny T, Ratner L, Friedberg JW, Herrera AF. *JCO Oncol Adv*. 2026 Jan;3(1):e2500143. doi: 10.1200/oa-25-00143. Epub 2026 Feb 26. <https://pubmed.ncbi.nlm.nih.gov/42577949/>

Submitted Manuscripts

None this cycle.

Lymphoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1918	S2114	S2207	S2308	A051902	A052101	AH0D2131
Baptist Memorial Health Care/Mid South NCORP Consortium	1	2	-	1	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	1	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	5	-	-	-	-	5
Cancer Research for the Ozarks NCORP	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	2	-	3	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	14	-	17	-	-	-
Cedars-Sinai Medical Center	1	-	6	2	-	-	3
City of Hope Comprehensive Cancer Center	11	-	-	16	-	-	22
Columbia University NCI Community Oncology Research Program	6	10	2	-	3	-	1
Dartmouth College - Dartmouth Cancer Center LAPS	-	2	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	8	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	7	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	6	-	9	-	-	-
Georgia CaRes	2	-	-	1	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	2	-	-	-
Henry Ford Hospital	-	1	-	2	-	-	3
Intermountain Medical Center	1	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	-	-	2	-	-	11
Kansas City Veterans Affairs Medical Center	-	-	-	1	-	2	-
Loyola University Medical Center	-	2	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	3	24	-	5	-	1	2
Michigan Cancer Research Consortium NCORP	8	-	1	1	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	1	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	6	-	-	-
Oregon Health and Science University	-	6	-	8	-	-	6
Pacific Cancer Research Consortium NCORP	-	13	1	4	-	-	1
Regents of the University of Michigan	-	-	-	3	-	-	-
Rhode Island Hospital	-	-	-	1	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	14	-	-	-
The Hawaii NCORP	1	-	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	11	1	23	-	5	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	1	-	2	-	-	1
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	9	-	-	-
University of Arizona LAPS	-	5	-	4	-	-	-
University of Arkansas for Medical Sciences	-	14	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	1	-	-
University of Colorado Cancer Center LAPS	-	-	-	11	-	-	1
University of Nebraska Medical Center	-	-	-	-	-	2	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	2	-	-	-
University of Rochester LAPS	-	13	9	25	8	20	33
University of Texas Health Science Center at San Antonio	-	-	2	1	-	-	1
University of Texas MD Anderson Cancer Center LAPS	-	-	-	24	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	12	-	1	11	-	-	13
Upstate Carolina Consortium Community Oncology Research Program	1	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	7	-	1	-	3	2
Wisconsin NCI Community Oncology Research Program	2	-	-	3	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	1	1
ALLIANCE	42	64	7	70	-	-	-
ECOG-ACRIN	17	19	-	53	-	-	-
NRG	7	12	5	26	-	-	-
Total	136	233	39	370	19	35	107

Lymphoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	ANHL1931	EA4231	EA4232
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-
Cedars-Sinai Medical Center	1	-	-
City of Hope Comprehensive Cancer Center	15	-	-
Columbia University NCI Community Oncology Research Program	3	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia CaRes	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-
Northwestern University LAPS	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
The Hawaii NCORP	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-
University of Arizona LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	1	-
University of Colorado Cancer Center LAPS	-	-	-
University of Nebraska Medical Center	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	10	-	2
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	33	1	2

